gpt-dict.com

Retatrutide for Type 2 Diabetes

Verdict: Published with Warning

Across 1 PubMed study, the evidence for Retatrutide in Type 2 Diabetes grades Tier B — preliminary evidence. Effective, but with safety or population caveats.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.52
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
85%
Highly consistent evidence
Evidence level
E7
Single small RCT

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L2 PubMedPrimary literature
0.55
L5 Clinical bodiesAuthoritative stance
0.55
L11 AI re-checkIndependent read
0.65
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.515
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (1)L2 · primary research & systematic reviews

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
PMID: 37385280 2023 RCT (phase 2, double-blind, placebo- and active-controlled, parallel-group) n = 281
Finding: Dose-dependent reduction in HbA1c and body weight. At 24 weeks, HbA1c fell by approximately 1.4-2.0 percentage points across retatrutide doses vs ~0.0 for placebo and ~1.4 for dulaglutide; substantial weight loss accompanied higher doses (mean ~ -16.9% at 12 mg by 24 weeks). GI adverse events were the most common and dose-related.
🟢 High quality Effect size: HbA1c reduction up to ~2.0 percentage points and body-weight reduction up to ~16.9% at higher doses by 24 weeks
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Retatrutide is not currently approved by the FDA and is considered an investigational medication, with Eli Lilly currently evaluating its safety and efficacy in clinical trials. source↗
L4b EU EFSA
Neutral
Retatrutide is not currently approved by the FDA and is considered an investigational medication. source↗
L4d TW TFDA / 衛福部
Cautious
Retatrutide is not currently approved by the FDA and is considered an investigational medication, with Eli Lilly currently evaluating its safety and efficacy in clinical trials. source↗
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬1 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-type2-diabetes-INT-retatrutide-001 繁體中文版 →